TRCT
CTNM

Tower Research Capital (TRC)’s Contineum Therapeutics CTNM Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.55K Buy
731
+607
+490% +$8.14K ﹤0.01% 3924
2025
Q4 		$1.42K Sell
124
-1,551
-93% -$17.7K ﹤0.01% 4696
2025
Q3 		$19.7K Sell
1,675
-5,780
-78% -$46.6K ﹤0.01% 3324
2025
Q2 		$29.6K Buy
7,455
+6,097
+449% +$26.5K ﹤0.01% 3404
2025
Q1 		$9.48K Buy
1,358
+415
+44% +$3.77K ﹤0.01% 3769
2024
Q4 		$13.8K Buy
943
+463
+96% +$7.33K ﹤0.01% 3504
2024
Q3 		$9.19K Buy
480
+386
+411% +$7.4K ﹤0.01% 3893
2024
Q2 		$1.66K Buy
+94
New +$1.51K ﹤0.01% 5116

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s CTNM Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Contineum Therapeutics (CTNM) stake by 490% in Q1 2026, buying an estimated $8.14K and bringing the position to 731 shares worth $9.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3924.

Tower Research Capital (TRC) first reported a position in CTNM in Q2 2024 and has held it in 8 quarters since. The position peaked at $29.6K in Q2 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Tower Research Capital (TRC) held 731 shares of Contineum Therapeutics worth $9.55K as of Q1 2026.
  • Tower Research Capital (TRC) bought 607 Contineum Therapeutics shares in Q1 2026, an estimated $8.14K.
  • Contineum Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3924 holding.
  • Tower Research Capital (TRC) first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Tower Research Capital (TRC)'s Contineum Therapeutics position peaked at $29.6K in Q2 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.